Physician profile
Daniel J Solverson
NPI 1316095805
$1,462.99
in general payments reported to CMS, 2019-2025
21 companies · $53.97 in 2025
The $53.97 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $183 · 2021: $125 · 2022: $536 · 2023: $228 · 2024: $163 · 2025: $53.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $382.71 | 2019-2024 | Hydrus Microstent, Clareon, Ngenuity |
| Allergan, INC. | $269.10 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $117.76 | 2019-2022 | |
| Abbvie INC. | $109.21 | 2022-2023 | Durysta, Lumigan, Alphagan P |
| New World Medical,INC. | $105.79 | 2022-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Horizon Therapeutics Plc | $90.70 | 2022-2023 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $64.20 | 2022-2025 | Eylea Hd |
| Thea Pharma INC. | $45.73 | 2023-2024 | Iyuzeh |
| Oyster Point Pharma, INC. | $43.00 | 2022 | |
| Apellis Pharmaceuticals, INC. | $29.63 | 2022-2023 | Syfovre |
| Glaukos Corporation | $26.94 | 2024 | Idose |
| Sight Sciences, INC. | $23.80 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $22.95 | 2021 | |
| Bausch & Lomb Americas INC. | $22.10 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $21.85 | 2025 | Xdemvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Genentech USA, INC. | $16.23 | 2023 | Vabysmo |
| Shire North American Group INC | $14.80 | 2019 | |
| Sun Pharmaceutical Industries INC. | $13.61 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.14 | 2019 | |
| Aerie Pharmaceuticals, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Solverson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.